BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vogelaar L, Spijker AV, van der Woude CJ. The impact of biologics on health-related quality of life in patients with inflammatory bowel disease. Clin Exp Gastroenterol. 2009;2:101-109. [PMID: 21694833 DOI: 10.2147/ceg.s4512] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Steenholdt C, Lorentsen RD, Petersen PN, Brynskov J. Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease. J Gastroenterol Hepatol 2022. [PMID: 36582016 DOI: 10.1111/jgh.16099] [Reference Citation Analysis]
2 Brunet-Houdard S, Monmousseau F, Berthon G, Des Garets V, Laharie D, Picon L, Fotsing G, Gargot D, Charpentier C, Buisson A, Trang-Poisson C, Dib N, Rusch E, Aubourg A; COQC-PIT Study Group. How are patients' preferences for anti-TNF influenced by quality of life? A discrete choice experiment in Crohn's disease patients. Scand J Gastroenterol 2022;57:1312-20. [PMID: 35722732 DOI: 10.1080/00365521.2022.2085057] [Reference Citation Analysis]
3 Fernández-lázaro D, Hernández-burgos N, Cobreros Mielgo R, García-lázaro S. Evaluación de actividad física como coadyuvante terapéutico para pacientes con enfermedad inflamatoria intestinal: una revisión. Investigación Clínica 2022;63:304-322. [DOI: 10.54817/ic.v63n3a08] [Reference Citation Analysis]
4 Aladraj H, Abdulla M, Guraya SY, Guraya SS. Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn's Disease: A Systematic Review. J Clin Med 2022;11. [PMID: 35807044 DOI: 10.3390/jcm11133743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Sadeghian I, Heidari R, Raee MJ, Negahdaripour M. Cell-penetrating peptide-mediated delivery of therapeutic peptides/proteins to manage the diseases involving oxidative stress, inflammatory response and apoptosis. J Pharm Pharmacol 2022:rgac038. [PMID: 35728949 DOI: 10.1093/jpp/rgac038] [Reference Citation Analysis]
6 Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, Kenneth C, Walker R, Kemp K, Borg-Bartolo S, Limdi JK, Taylor J, Townsend T, Subramanian S, Storey D, Assadsangabi A, Stansfield C, Smith P, Byrne D, De Silvestri A, Selinger CP. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther 2022;55:856-66. [PMID: 34935160 DOI: 10.1111/apt.16742] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
7 Au M, Mitrev N, Leong RW, Kariyawasam V. Dual biologic therapy with ocrelizumab for multiple sclerosis and vedolizumab for Crohn’s disease: A case report and review of literature. World J Clin Cases 2022; 10(8): 2569-2576 [DOI: 10.12998/wjcc.v10.i8.2569] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Graff LA, Fowler S, Jones JL, Benchimol EI, Bitton A, Huang JG, Kuenzig ME, Kaplan GG, Lee K, Mukhtar MS, Tandon P, Targownik LE, Windsor JW, Bernstein CN. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Mental Health and Quality of Life. J Can Assoc Gastroenterol 2021;4:S46-53. [PMID: 34755039 DOI: 10.1093/jcag/gwab031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M. Small Molecule Drugs in Inflammatory Bowel Diseases. Pharmaceuticals (Basel) 2021;14:637. [PMID: 34209234 DOI: 10.3390/ph14070637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Jairath V, Chan K, Lasch K, Keeping S, Agboton C, Blake A, Patel H. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol 2021;15:711-22. [PMID: 33599181 DOI: 10.1080/17474124.2021.1880319] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Kuenzig ME, Manuel DG, Donelle J, Benchimol EI. Life expectancy and health-adjusted life expectancy in people with inflammatory bowel disease. CMAJ 2020;192:E1394-402. [PMID: 33168761 DOI: 10.1503/cmaj.190976] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
13 Chew C, Aguiar M, Bansback N, Law MR, Harrison M. Patient perspectives on the British Columbia Biosimilars Initiative: a qualitative descriptive study. Rheumatol Int 2021. [PMID: 33961101 DOI: 10.1007/s00296-021-04874-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Teich N, Grümmer H, Jörgensen E, Liceni T, Holtkamp-Endemann F, Fischer T, Hohenberger S. Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months. BMC Gastroenterol 2021;21:161. [PMID: 33845784 DOI: 10.1186/s12876-021-01747-z] [Reference Citation Analysis]
15 Beraldo RF, Baima JP, Barros JRD, Renosto FL, Saad-hossne R, Sassaki LY. The Impact of a Real-Life Inflammatory Bowel Disease Education Course for Brazilian Physicians from the Perspective of Its Participants. OJGas 2021;11:151-160. [DOI: 10.4236/ojgas.2021.119016] [Reference Citation Analysis]
16 Gourdonneau A, Bruneau L, Ruemmele FM, Norsa L, Takeda A, Le Gall C, Clouzeau H, Rebouissoux L, Dabadie A, Bridoux-Henno L, Rebeuh J, Thomassin N, Viala J, Willot S, Breton A, Coopman S, Spyckerelle C, Languepin J, Bertrand V, Mouterde O, Degas V, Bonneton M, Lemale J, Destombe S, Billiemaz K, Caron N, Borderon C, Dupont C, Triolo V, Jobert A, Lamireau T, Enaud R. Clinical Remission and Psychological Management are Major Issues for the Quality of Life in Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr 2021;72:74-9. [PMID: 32740538 DOI: 10.1097/MPG.0000000000002865] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Teich N, Bläker M, Holtkamp-Endemann F, Jörgensen E, Stallmach A, Hohenberger S. Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn's Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany. Inflamm Intest Dis 2021;6:48-60. [PMID: 33850839 DOI: 10.1159/000512159] [Reference Citation Analysis]
18 D'Amico F, Peyrin-Biroulet L, Vandromme L, Bouhnik Y, Faure P, Nahon S, Hagege H, Hebuterne X, Benkhalifa S, Nachury M. Motivation to pursue anti-TNFα treatment in patients with Crohn's disease - the SPACE motivation study. Dig Liver Dis 2020;52:995-1001. [PMID: 32532602 DOI: 10.1016/j.dld.2020.05.032] [Reference Citation Analysis]
19 Parra RS, Chebli JM, Amarante HM, Flores C, Parente JM, Ramos O, Fernandes M, Rocha JJ, Feitosa MR, Feres O, Scotton AS, Nones RB, Lima MM, Zaltman C, Goncalves CD, Guimaraes IM, Santana GO, Sassaki LY, Hossne RS, Bafutto M, Junior RL, Faria MA, Miszputen SJ, Gomes TN, Catapani WR, Faria AA, Souza SC, Caratin RF, Senra JT, Ferrari ML. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-5882 [PMID: 31636478 DOI: 10.3748/wjg.v25.i38.5862] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
20 Andersen MJ, Yvellez OV, El Jurdi K, Sossenheimer PH, Lei D, Pearl TA, Zmeter N, Rubin DT. Simplification of Validated Patient-Reported Outcome Instruments in Inflammatory Bowel Disease. Crohn's & Colitis 360 2019;1. [DOI: 10.1093/crocol/otz043] [Reference Citation Analysis]
21 Jansen JP, Khalid JM, Smyth MD, Patel H. The number needed to treat and relevant between-trial comparisons of competing interventions. Clinicoecon Outcomes Res 2018;10:865-71. [PMID: 30588048 DOI: 10.2147/CEOR.S180491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
22 Jones JL, Nguyen GC, Benchimol EI, Bernstein CN, Bitton A, Kaplan GG, Murthy SK, Lee K, Cooke-Lauder J, Otley AR. The Impact of Inflammatory Bowel Disease in Canada 2018: Quality of Life. J Can Assoc Gastroenterol 2019;2:S42-8. [PMID: 31294384 DOI: 10.1093/jcag/gwy048] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
23 Liu R, Tang A, Wang X, Shen S. Assessment of Quality of Life in Chinese Patients With Inflammatory Bowel Disease and their Caregivers. Inflamm Bowel Dis 2018;24:2039-47. [PMID: 29788383 DOI: 10.1093/ibd/izy099] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
24 Katsanos KH, Papadakis KA. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics. Gut Liver. 2017;11:455-463. [PMID: 28486793 DOI: 10.5009/gnl16308] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 15.8] [Reference Citation Analysis]
25 Stanic Benic M, Giljaca V, Vlahovic-palcevski V. The impact of biological interventions on health-related quality of life in adults with Crohn's disease. Cochrane Database of Systematic Reviews 2018. [DOI: 10.1002/14651858.cd012973] [Reference Citation Analysis]
26 Chouliaras G, Margoni D, Dimakou K, Fessatou S, Panayiotou I, Roma-Giannikou E. Disease impact on the quality of life of children with inflammatory bowel disease. World J Gastroenterol 2017; 23(6): 1067-1075 [PMID: 28246481 DOI: 10.3748/wjg.v23.i6.1067] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
27 La Barbera D, Bonanno B, Rumeo MV, Alabastro V, Frenda M, Massihnia E, Morgante MC, Sideli L, Craxì A, Cappello M, Tumminello M, Miccichè S, Nastri L. Alexithymia and personality traits of patients with inflammatory bowel disease. Sci Rep 2017;7:41786. [PMID: 28150800 DOI: 10.1038/srep41786] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
28 Velonias G, Conway G, Andrews E, Garber JJ, Khalili H, Yajnik V, Ananthakrishnan AN. Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2017;23:283-8. [PMID: 28079625 DOI: 10.1097/MIB.0000000000001008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
29 Zhang ZM, Li W, Jiang XL. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials. Gut Liver. 2016;10:262-274. [PMID: 26780088 DOI: 10.5009/gnl15042] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
30 Cappello M, Morreale GC. The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol. 2016;9:51-62. [PMID: 27656094 DOI: 10.4137/cgast.s38203] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
31 Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies. Inflamm Bowel Dis 2016;22:1999-2015. [PMID: 27135483 DOI: 10.1097/MIB.0000000000000772] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 10.7] [Reference Citation Analysis]
32 Vogelaar L, van den Berg-Emons R, Bussmann H, Rozenberg R, Timman R, van der Woude CJ. Physical fitness and physical activity in fatigued and non-fatigued inflammatory bowel disease patients. Scand J Gastroenterol 2015;50:1357-67. [PMID: 25966749 DOI: 10.3109/00365521.2015.1046135] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
33 Morreale GC, Cappello M, Craxì A. Laboratory Tests in Crohn’s Disease. Crohn’s Disease 2016. [DOI: 10.1007/978-3-319-23066-5_3] [Reference Citation Analysis]
34 Yarur AJ, Rubin DT. Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2015;21:1709-18. [PMID: 25901974 DOI: 10.1097/MIB.0000000000000380] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
35 Wright EK, Kamm MA. Impact of drug therapy and surgery on quality of life in Crohn's disease: a systematic review. Inflamm Bowel Dis 2015;21:1187-94. [PMID: 25895008 DOI: 10.1097/MIB.0000000000000271] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
36 Augustine JM, Lee JK, Armstrong EP. Health outcomes and cost-effectiveness of certolizumab pegol in the treatment of Crohn's disease. Expert Rev Pharmacoecon Outcomes Res 2014;14:599-609. [PMID: 25209304 DOI: 10.1586/14737167.2014.957680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Dave M, Papadakis KA, Faubion WA Jr. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am 2014;43:405-24. [PMID: 25110250 DOI: 10.1016/j.gtc.2014.05.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 5.2] [Reference Citation Analysis]
38 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment Pharmacol Ther 2014;39:1349-62. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 136] [Cited by in F6Publishing: 108] [Article Influence: 15.1] [Reference Citation Analysis]
39 Yarur AJ, Abreu MT, Deshpande AR, Kerman DH, Sussman DA. Therapeutic drug monitoring in patients with inflammatory bowel disease. World J Gastroenterol 2014; 20(13): 3475-3484 [PMID: 24707130 DOI: 10.3748/wjg.v20.i13.3475] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
40 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther 2014;39:660-71. [PMID: 24506179 DOI: 10.1111/apt.12644] [Cited by in Crossref: 116] [Cited by in F6Publishing: 91] [Article Influence: 12.9] [Reference Citation Analysis]
41 Sherman M, Tsynman DN, Kim A, Arora J, Pietras T, Messing S, St Hilaire L, Yoon S, Decross A, Shah A, Saubermann L. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014;15:174-9. [PMID: 24373601 DOI: 10.1111/1751-2980.12125] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
42 Dewint P, Hansen BE, Verhey E, Oldenburg B, Hommes DW, Pierik M, Ponsioen CI, van Dullemen HM, Russel M, van Bodegraven AA, van der Woude CJ. Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014;63:292-9. [PMID: 23525574 DOI: 10.1136/gutjnl-2013-304488] [Cited by in Crossref: 153] [Cited by in F6Publishing: 157] [Article Influence: 17.0] [Reference Citation Analysis]
43 Kalafateli M, Triantos C, Theocharis G, Giannakopoulou D, Koutroumpakis E, Chronis A, Sapountzis A, Margaritis V, Thomopoulos K, Nikolopoulou V. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience. Ann Gastroenterol 2013;26:243-8. [PMID: 24714279] [Reference Citation Analysis]